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Aims: Renin-angiotensin system inhibitors (RASi) are the most effective treatments
for diabetic kidney disease but significant residual renal risk remains, possibly
because of other mechanisms of kidney disease progression unrelated to RAS that
may be present. Sodium-glucose co-transporter-2 inhibitors reduce albuminuria
and may complement RASi by offering additional renal protection. This post hoc
analysis investigated the effects of dapagliflozin on cardio-renal risk factors in
patients with type 2 diabetes (T2D) with increased albuminuria treated with or
without RASi at baseline.
Materials and methods: We evaluated the effects of dapagliflozin 10 mg/day over
12–24 weeks across 13 placebo-controlled studies in patients with T2D with a uri-
nary albumin-to-creatinine ratio (UACR) ≥30 mg/g at baseline. Patients were divided
into two subgroups based on treatment with or without RASi at baseline.
Results: Compared with patients with RASi at baseline (n = 957), patients without
RASi (n = 302) were younger, had a shorter duration of diabetes (7 vs. 12 years),
higher estimated glomerular filtration rate (eGFR) and lower UACR, serum uric acid
(sUA), body weight and systolic blood pressure. Placebo-adjusted treatment effects
of dapagliflozin on UACR, eGFR, glycated haemoglobin and haematocrit over
24 weeks were similar across groups. Mean reductions in body weight and sUA were
more distinct in patients without RASi treatment at baseline.
Conclusions: Treatment with dapagliflozin over 24 weeks provides similar clinically
relevant improvements in metabolic and haemodynamic parameters, and similar
reductions in UACR, in patients with T2D with elevated albuminuria treated with or
without RASi at baseline.
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1 | INTRODUCTION
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as
dapagliflozin, lower blood glucose levels by blocking glucose reuptake
in the proximal tubule, resulting in urinary glucose excretion.1 Beyond
their glucose-lowering effect, evidence from recent cardiovascular
(CV) outcomes trials (CVOTs)2-4 indicates that whereas the effects of
SGLT-2 inhibitors on major adverse CV events might be limited to
patients with established CV disease, the beneficial effects on heart
failure and renal function might be applicable to a broad population of
patients with type 2 diabetes (T2D).5-7 In particular, in these trials,
SGLT-2 inhibitors delayed the progression of nephropathy.2,3,8 Given
the large burden of both CV disease and diabetic kidney disease in
patients with T2D—despite optimal treatment of CV and renal risk
factors using a multifactorial intervention9—these SGLT-2 inhibitor-
induced cardiac and renal effects are highly salutary.
However, currently, it is unclear how the use of background
medication may potentially alter the effects of SGLT-2 inhibition on
cardiac and renal risk factors, such as urinary albumin-to-creatinine
ratio (UACR), blood pressure (BP) or serum uric acid (sUA), as they
have only reported the effect of background medication on out-
comes. Most important in this regard are the renin-angiotensin sys-
tem inhibitors (RASi): angiotensin-converting enzyme inhibitors and
angiotensin-II receptor blockers. These drugs are known to affect
systemic haemodynamics, reverse cardiac remodelling after injury
and modulate renal haemodynamics by dilating the renal efferent
arteriole. It is important to ascertain whether the beneficial effects
of dapagliflozin on cardiac and renal risk factors are modified by
concomitant RAS inhibition and, equally important, whether RAS
inhibition could alter the safety and tolerability of SGLT-2 inhibitors.
Therefore, in the current post hoc analysis of previously
reported dapagliflozin studies, we investigated the effect of
dapagliflozin on multiple important markers of cardiac and kidney
function as well as on safety aspects in patients with T2D treated
with or without RASi.
2 | MATERIALS AND METHODS
2.1 | Study design
This was a post hoc analysis of data pooled from 13 previously
reported phase II and III, randomized, placebo- or active-controlled,
12- or 24-week studies conducted during 2005–2012 (Table S1; see
Supporting Information).10-22 The studies included patients with T2D
aged ≥18 years, with body mass index ≤40–45 kg/m2 and glycated
haemoglobin (HbA1c) ≥6.5%–12% (47.5–107.7 mmol/mol). The pro-
tocols of the original studies used for this post hoc analysis did not
require RASi use as an entry criterion. In this analysis, patients with
T2D with a UACR ≥30 mg/g at baseline were divided into two groups:
patients who received RASi at baseline (with RASi treatment) and
patients who did not receive RASi at baseline (without RASi treat-
ment). Single spot urine samples were collected at each study visit.
The pooled patient population was randomized to receive
dapagliflozin 10 mg/day or placebo for up to 24 weeks.
2.2 | Outcome measures
Baseline demographics and disease characteristics were assessed.
Changes in the following parameters were assessed from baseline
over the 24-week treatment period with dapagliflozin versus pla-
cebo: UACR, estimated glomerular filtration rate (eGFR), HbA1c,
haematocrit, body weight, sUA, systolic BP (SBP) and diastolic BP
(DBP). We analysed the impact of change in UACR on the overall
population adjusting for UACR, age, sex, race, body weight, SBP,
eGFR and RASi treatment at baseline. The overall safety profile,
including adverse events (AEs) and serious AEs (SAEs), was also
assessed.
2.3 | Statistical analyses
Descriptive statistics were used for presenting baseline characteristics
and safety data. For efficacy parameters, the mean change from base-
line values and 95% confidence intervals (CIs) were derived using a lon-
gitudinal repeated-measures mixed model with fixed terms for study,
treatment, week, subgroup, week-by-treatment interaction, treatment-
by-subgroup interaction and treatment-by-week-by-subgroup interac-
tion, as well as the fixed covariates of baseline, baseline-by-study and
baseline-by-week interactions. In addition, for the percentage change in
UACR, a longitudinal repeated-measures mixed model pooling sub-
groups was performed, with fixed terms for study, treatment, week and
week-by-treatment interaction, as well as the fixed covariates of base-
line, baseline-by-study, baseline-by-week interactions and baseline age,
sex, race, weight, SBP, eGFR and treatment with RASi at baseline.
UACR values were log transformed (using the natural logarithm) and
then exponentiated back to the original scale. Group differences com-
paring the renin-angiotensin system inhibitors (RASi) blockade groups
for continuous data were tested using ANOVA with group and study in
the model. All statistical analyses were performed using SAS® version
9.2 (SAS Institute Inc., Cary, North Carolina).
3 | RESULTS
3.1 | Disposition and baseline characteristics
Demographic and baseline characteristics are shown in Table 1. Of
the 1259 patients analysed, at baseline most (n = 957) participants
among these studies were prescribed RASi treatment as compared
with the group without RASi treatment (n = 302). Patients without
RASi treatment compared with those with RASi treatment at baseline
were younger (by approximately 5 years), had a shorter duration of
diabetes (approximately 7 vs. 12 years), had higher eGFR and had
lower UACR, sUA, body weight and SBP at baseline (Table 1). In both
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groups, most patients were white and there were more men than
women.
3.2 | Effect of dapagliflozin on urinary albumin-to-
creatinine ratio, estimated glomerular filtration rate,
glycated haemoglobin and haematocrit
The observed changes in the placebo-adjusted treatment effects of
dapagliflozin at week 24 in UACR (Figure 1A), eGFR (Figure 1B) and
HbA1c (Figure 1C) were of similar magnitudes in patients without
RASi treatment compared with those with RASi treatment at baseline.
The effect of dapagliflozin on haematocrit was similar in patients with-
out RASi treatment compared with those with RASi treatment at
baseline (Figure 1D). Table S2 (see Supporting Information) shows
more detailed data for these parameters.
3.3 | Effect of dapagliflozin on body weight, serum
uric acid, and systolic and diastolic blood pressure
The placebo-adjusted mean reductions (95% CI at week 24) in body
weight and sUA were more pronounced in patients without RASi
treatment compared with those treated with RASi at baseline at week
TABLE 1 Baseline characteristics
With RASi (N = 957) Without RASi (N = 302)
Characteristic PBO n = 481
DAPA 10 mg
n = 476
Total N = 957 PBO n = 146
DAPA 10 mg
n = 156
Total N = 302 P-valuea
Age, years, mean (SD) 61.6 (8.4) 61.1 (9.2) 61.4 (8.8) 56.8 (11.2) 55.4 (10.8) 56.1 (11.0) 0.0095
Women, n (%) 170 (35.3) 168 (35.3) 338 (35.3) 58 (39.7) 64 (41.0) 122 (40.4) 0.0554
Race, n (%)
White 414 (86.1) 406 (85.3) 820 (85.7) 104 (71.2) 110 (70.5) 214 (70.9)
Black or African American 11 (2.3) 24 (5.0) 35 (3.7) 3 (2.1) 6 (3.8) 9 (3.0) <0.0001
Asian 34 (7.1) 37 (7.8) 71 (7.4) 31 (21.2) 32 (20.5) 63 (20.9)
Othera 22 (4.6) 9 (1.9) 31 (3.2) 8 (5.5) 8 (5.1) 16 (5.3)
Duration of T2D, years,
mean (SD)
11.6 (8.8) 11.6 (8.4) 11.6 (8.6) 6.9 (7.7) 7.6 (9.3) 7.2 (8.6) 0.9592
UACR, mg/g, median
(Q1, Q3)
80.0 (45.0, 195.0) 81.5 (47.0, 192.5) 81.0 (46.0, 193.0) 60.0
(41.0, 150.0)
64.1 (40.0, 132.0) 61.5 (41.0, 138.0) 0.3279
(min, max) (30.0, 2584.0) 30.0, 3544.0 (30.0, 3544.0) 30.0, 2089.0 30.0, 1888.0 (30.0, 2089.0)
Body weight, kg,
mean (SD)
92.4 (19.0) 94.0 (20.9) 93.2 (20.0) 85.9 (22.2) 86.2 (20.8) 86.1 (21.4) 0.1000
HbA1c, %, mean (SD) 8.3 (0.9) 8.3 (0.9) 8.3 (0.9) 8.5 (1.1) 8.4 (0.9) 8.4 (1.0) 0.8603
sUA, mg/dL, mean (SD) 5.9 1.7 5.9 1.6 5.9 1.6 5.3 1.6 5.3 1.6 5.3 1.6 0.0612
UGCR, g/g, mean (SD) 3.1 (14.4b) 3.0 (9.8c) 3.0 (12.3) 9.1 (18.8d) 7.5 (18.7e) 8.3 (18.7) 0.0501
SBP, mmHg, mean (SD) 137.0 (14.6f) 139.3 (14.5g) 138.2 (14.6) 130.8 (14.3h) 129.1 (14.0i) 129.9 (14.1) <0.0001
DBP, mmHg, mean (SD) 79.3 (9.4f) 79.3 (9.6g) 79.3 (9.5) 78.7 (8.2h) 78.2 (9.5i) 78.4 (8.9) 0.0006
eGFR, mL/min/1.73 m2,
mean (SD)
78.8 (21.9) 78.3 (21.0) 78.5 (21.5) 89.7 (24.0) 89.4 (24.4) 89.6 (24.2) 0.0379
<30, n (%) 1 (0.2) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0)
≥30 to <45, n (%) 15 (3.1) 22 (4.6) 37 (3.9) 2 (1.4) 1 (0.6) 3 (1.0)
≥45 to <60, n (%) 70 (14.6) 66 (13.9) 136 (14.2) 12 (8.2) 14 (9.0) 26 (8.6) <0.0001
≥60 to <90, n (%) 258 (53.6) 258 (54.2) 516 (53.9) 66 (45.2) 69 (44.2) 135 (44.7)
≥90, n (%) 137 (28.5) 130 (27.3) 267 (27.9) 66 (45.2) 72 (46.2) 138 (45.7)
Diuretic use, n (%) 217 (45.1) 211 (44.3) 428 (44.7) 16 (11.0) 11 (7.1) 27 (8.9) <0.0001
Loop diuretic, n (%) 95 (19.8) 84 (17.6) 179 (18.7) 10 (6.8) 6 (3.8) 16 (5.3) <0.0001
Thiazide diuretic, n (%) 147 (30.6) 140 (29.4) 287 (30.0) 6 (4.1) 6 (3.8) 12 (4.0) <0.0001
Abbreviations: DAPA, dapagliflozin; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; PBO, placebo;
RASi, renin-angiotensin system inhibitors, SBP, systolic blood pressure; SD, standard deviation; sUA, serum uric acid; T2D, type 2 diabetes; UACR, urinary
albumin-to-creatinine ratio; UGCR, urinary glucose-to-creatinine ratio.
aRASi versus without RASi groups; aincludes patients with a reported race of American Indian/Alaska Native, Native Hawaiian/other Pacific Islander or
other; bn = 462; cn = 455; dn = 143; en = 151; fn = 473; gn = 471; hn = 139; in = 151.
SCHOLTES ET AL. 551
24; that is, −2.60 kg (−3.31, −1.90) versus −1.76 kg (−2.19, −1.34)
(P = 0.0569 treatment by RASi subgroup interaction; Figure 1E) and
−0.61 (−0.83, −0.40) mg/dL versus −0.36 (−0.49, −0.23) mg/dL
(P = 0.0433 treatment by RASi subgroup interaction; Figure 1F),
respectively. Although a decrease was observed in both groups, the
placebo-adjusted mean reductions in SBP and DBP at week 24 were
numerically greater in patients without RASi treatment compared with
those with RASi treatment at baseline (Figure 1G and 1H). Similarly,
placebo-adjusted mean reduction in SBP and DBP at week 24 was
numerically greater in patients who were not on diuretics than in those
F IGURE 1 A, UACR. B, eGFR. C, HbA1c. D, Haematocrit. E, Body weight. F, sUA. G, SBP. H, DBP. Placebo-adjusted changes in CV and renal
risk factors in patients receiving dapagliflozin 10 mg/day with or without RASi treatment at baseline. Abbreviations: Adj., adjusted; CI, confidence
interval; CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; RASi, renin-
angiotensin system inhibitors; SBP, systolic blood pressure; sUA, serum uric acid; UACR, urinary albumin-to-creatinine ratio
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on diuretics [−4.40 (−6.03, −2.77) vs. –3.17 (−5.91, −0.43); −2.05
(−3.12, −0.98) vs. –2.01 (−3.60, −0.42)].
3.4 | Effect of covariates on placebo-adjusted
change in urinary albumin-to-creatinine ratio in all
patients receiving dapagliflozin
The placebo-adjusted effect of dapagliflozin treatment on UACR was
not affected by treatment with RASi at baseline and was largely
independent of other covariates such as age, race, body weight, SBP
and eGFR (Figure 2).
3.5 | Safety
Overall, AEs were more common in patients treated with RASi (who
were also older and had a longer duration of T2D) compared with
patients without RASi treatment. However, among patients with RASi
treatment, the AE profile was similar in the placebo and dapagliflozin
treatment groups (Table 2). Among the group without RASi treatment,
the proportion of patients with at least one AE was greater in the
dapagliflozin-treated patients than in the placebo-treated patients
(Table 2).
4 | DISCUSSION
We show here, using a pooled analysis of 13 phase II and III studies in
patients with T2D and increased albuminuria, that treatment with the
SGLT-2 inhibitor dapagliflozin over 24 weeks provides similar clinically
relevant improvements in CV and renal risk parameters, irrespective
of treatment with RASi at baseline.
The cardio-renal protective effects of SGLT-2 inhibitors have
been recently established by three large CVOTs.2-4 However, it is
unclear whether the use of co-medication, specifically RASi, could
modulate the beneficial effects on cardiac and renal outcomes and the
safety profiles of SGLT-2 inhibitors. Thus, in this post hoc analysis we
investigated the effect of dapagliflozin on multiple markers of cardio-
renal function, as well as on safety aspects in patients with T2D
treated with or without RASi before dapagliflozin initiation.
Regarding CV disease markers, an important observation was that
regardless of RAS inhibition at baseline, haematocrit levels were
increased, which could indicate either volume contraction23,24 or
increase in erythropoiesis.25 Volume contraction corresponds to one
of the main hypotheses for the CV benefits observed in the SGLT-2
inhibitor CVOTs: an increase in haematocrit, resulting in beneficial
F IGURE 2 Placebo-adjusted percentage change in UACR for all
patients receiving dapagliflozin 10 mg/day. Abbreviations: Adj.,
adjusted; CI, confidence interval; eGFR, estimated glomerular
filtration rate; RASi, renin-angiotensin system inhibitors; SBP, systolic
blood pressure; UACR, urinary albumin-to-creatinine ratio
TABLE 2 Summary of adverse events
With RASi (N = 957) Without RASi (N = 302)
Description PBO n = 481 DAPA 10 mg n = 476 PBO n = 146 DAPA 10 mg n = 156
At least one AE 294 (61.1) 313 (65.8) 75 (51.4) 100 (64.1)
AEs leading to study drug discontinuation 29 (6.0) 24 (5.0) 4 (2.7) 5 (3.2)
At least one hypoglycaemic event 85 (17.7) 90 (18.9) 11 (7.5) 13 (8.3)
At least one SAE 51 (10.6) 41 (8.6) 2 (1.4) 6 (3.8)
SAEs leading to study drug discontinuation 10 (2.1) 0 (0.0) 1 (0.7) 1 (0.6)
Deaths 4 (0.8) 3 (0.6) 0 (0.0) 1 (0.6)
Abbreviations: AE, adverse event; DAPA, dapagliflozin; PBO, placebo; RASi, renin-angiotensin system inhibitors; SAE, serious adverse event. Data are
represented as n (%). Data shown include non-serious/serious AEs with onset on or after the first date of treatment and on or before the last day of
treatment plus 4 days/30 days or up to and including the start date of the long-term period or up to the follow-up visit if earlier. Only hypoglycaemia
reported as an SAE is included in the AE, related AE, SAE, related SAE and AE leading to discontinuation summaries.
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cardiac haemodynamics.23 For example, Inzucchi et al showed in a
mediation analysis of the EMPA-REG OUTCOME trial that the change
in haematocrit from baseline mediated 51.8% of the effect of
empagliflozin versus placebo in the reduction of the risk of CV
death.23 Conversely, although an increase in erythropoiesis could be a
complementary mechanism for the increased levels of haematocrit,
the extent to which this mechanism contributes to the CV benefits
observed with empagliflozin is not clear.25
As expected,3 a decrease in body weight was observed in patients
treated with dapagliflozin. However, in combination with RASi the
reduction in body weight was not as pronounced as without RASi. Pre-
vious studies have shown that the glucose-lowering efficacy of SGLT-2
inhibitors depends on renal function.26 In parallel, attenuation of weight
loss would be expected with declining renal function. However, surpris-
ingly, the reduction in body weight is found to be independent of
eGFR27 and the underlying mechanism is still not understood. Given
the post hoc nature of the analysis, any proffered mechanism for this
weight loss pattern would probably be speculative.
In the present analysis, a decrease in sUA levels was observed in
patients treated with or without RASi. To the extent that this may
have CV benefit this is a salutary effect. Fractional excretion of UA
has been shown to be related to urinary glucose excretion.28 Keeping
in mind that in the present analysis the majority of the patients with-
out RASi had normal kidney function, the glucose-mediated excretion
of UA could possibly be larger compared with that in patients with
RAS inhibition.
The most cited explanation for the renoprotective properties of
SGLT-2 inhibitors is their ability to activate tubuloglomerular
feedback,29-32 thereby reducing intraglomerular pressure.33 Clinically,
this is reflected in a decline in eGFR upon initiation of SGLT-2 inhibi-
tion and a rapid and sustained reduction in albuminuria,34 followed by
stabilization and preservation of kidney function. The same was
observed in the current analysis and has been demonstrated in other
studies of other SGLT-2 inhibitors.2,4 The beneficial effects of SGLT-2
inhibition on renal outcomes, such as eGFR, have been shown in the
EMPA-REG OUTCOME trial, CREDENCE, CANVAS Program and
DECLARE-TIMI 58 trial.2,4,7,36 However, none of these studies
reported whether SGLT-2 inhibitors according to baseline RASi use
modulated the effect on UACR.
Our analysis also showed that the magnitude of UACR reduction
was similar in patients treated with and without RASi at baseline. This
is in contrast to previous literature in which it has been proposed that
SGLT-2 inhibition with concomitant RASi may synergistically boost
the alternative RAS axis, leading to upregulation of angiotensin
(1–7).37 In our analysis, we did not find modulation by RASi or any
indication of a possible synergistic effect, thus the effect of RASi is
probably smaller. This would also explain why the magnitude of UACR
reduction in our analysis was comparable in patients with and without
RASi at baseline.
Interestingly, the placebo-adjusted treatment effect of
dapagliflozin-induced UACR reduction was mostly independent of
haemodynamic, metabolic, biochemical or physical factors. Neverthe-
less, these data suggest possible differences between sexes.38,39
This largely independent UACR reduction is in line with previous
findings with dapagliflozin, empagliflozin and canagliflozin.34,40,41 The
albuminuria- and UACR-lowering effect of dapagliflozin is known to
show large interindividual variations, and may only be partly explained
by haemodynamic factors such as eGFR and SBP.40,42 Apparently,
other effects of dapagliflozin, such as reduction in intraglomerular
hypertension, account for the albuminuria-lowering properties,
although we cannot eliminate confounding caused by measurement
variability.
With respect to safety, concomitant use of RASi and dapagliflozin
appears to show a safety profile similar to the known profile of
dapagliflozin (i.e. no increase in drug discontinuation because of AEs
or SAEs).
The present analysis has some limitations. First, patients with
RASi had a longer duration of T2D and higher UACR and SBP, as well
as lower eGFR, compared with those without RASi use at baseline.
Thus, in general, patients with RASi had more severe chronic kidney
disease and had more comorbid conditions at baseline. Further, this
was a post hoc analysis of 13 randomized controlled studies, and the
original studies were not designed to assess the interaction of
dapagliflozin with concurrent RASi use. Hence, patients were not ran-
domized according to treatment with or without RAS inhibition. Con-
sequently, baseline characteristics differed between the dapagliflozin
and placebo groups and this limited the analysis. Therefore, this analy-
sis can only be interpreted as hypothesis generating. Another limita-
tion was the heterogeneity across the pooled clinical studies, possibly
caused by differences in study design, duration and baseline charac-
teristics, which may cause variability in the treatment effects esti-
mated across studies.
5 | CONCLUSIONS
In this post hoc analysis, the placebo-adjusted treatment effects of
dapagliflozin on UACR, eGFR, HbA1c and haematocrit over 24 weeks
were similar between patients with and without RAS inhibition at base-
line. There were no additional safety findings for the dapagliflozin/RASi
combination compared with RAS inhibition alone. Therefore, our data
suggest that the use of RASi in combination with SGLT-2 inhibitors does
not impact the biomarkers associated with CV and kidney function.
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